Skip to main content

Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab

Abstract

Malignant gliomas have long been a therapeutic dilemma in neuro-oncology, with a poor overall prognosis. Standard treatment, consisting of primary resection, followed by radiation therapy and temozolomide, has improved prognosis. Recently, studies have looked at the addition of bevacizumab (Avastin), a humanized murine IgG1 monoclonal antibody against vascular endothelial growth factor-A, to conventional regiments. Bevacizumab gained US FDA approval for single agent use in recurrent glioblastoma in 2009. Known side effects of bevacizumab include increased risk of arterial and venous thromboembolism, as well as hemorrhage. With emerging data for the use of bevacizumab in malignant gliomas, the extent of risks such as bleeding and thrombosis in patients with primary brain tumors treated with bevacizumab remains unknown. Here, we present only the second reported case of dural venous sinus thrombosis during treatment with bevacizumab and the first reported case for a primary glioma treated with temozolomide, radiation, and bevacizumab.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. The Oncologist 14:1131–1138

    PubMed  Article  CAS  Google Scholar 

  2. Elice F, Jacoub J, Rickles FR, Falanga A, Rodeghiero F (2008) Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 83:862–870

    PubMed  Article  CAS  Google Scholar 

  3. Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69:25–33

    PubMed  Article  CAS  Google Scholar 

  4. Khorana AA, Rao MV (2007) Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res 120:S41–S50

    PubMed  Article  Google Scholar 

  5. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380

    PubMed  Article  CAS  Google Scholar 

  6. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Herndon JE, Kirkpatrick J, Gururangan S, Baily L, Friedman AH, Friedman HS (2009) Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 27S:2015. ASCO Annual meeting proceedings

  7. Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vrendenburgh JJ (2008) Bevacizumab plus irinotecan in recurrent WHO grade III malignant gliomas. Clin Cancer Res 14:7068–7073

    PubMed  Article  CAS  Google Scholar 

  8. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745

    PubMed  Article  CAS  Google Scholar 

  9. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Darell BD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4749

    PubMed  Article  CAS  Google Scholar 

  10. Vrendenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259

    Article  Google Scholar 

  11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    PubMed  Article  CAS  Google Scholar 

  12. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S, Friedman HS (2010) Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). J ClinOncol 28S:2023. ASCO Annual meeting proceedings

  13. Health canada endorsed important safety Information on Avastin (bevacizumab). Available from http://www.hc-sc.gc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/avastin_pc-cp-eng.pdf. Accessed 10 July 2010

  14. Avastin (bevacizumab) Prescribing Information. Available from http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed 10 July 2010

  15. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285

    PubMed  Article  CAS  Google Scholar 

  16. Pan E, Tsai JS, Mitchell SB (2009) Retrospective study of venous thromboembolic and intracereberal hemorrhagic events in glioblastoma patients. Anticancer Res 10:4309–4313

    Google Scholar 

  17. Ozen A, Cicin I, Sezer A, Uzunoglu S, Saynak M, Genchellac H, Karagol H (2009) Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab. J Can Res Ther 5:130–132

    Article  Google Scholar 

  18. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, Investigators ISCVT (2004) Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis. Stroke 35:664–670

    PubMed  Article  Google Scholar 

  19. Filippidis A, Kapsalaki E, Patramani G, Fountas KN (2009) Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment. Neurosurg Focus 27:E3

    PubMed  Article  Google Scholar 

  20. Razier JJ, DeAngelis LM (2000) Cerebral sinus thrombosis diagnosed by MRI and MR venography in cancer patients. Neurology 54:1222–1226

    Google Scholar 

Download references

Conflicts of interest

Actual or potential conflicts of interest do not exist.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. A. Vargo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vargo, J.A., Snelling, B.M., Ghareeb, E.R. et al. Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. J Neurooncol 104, 595–598 (2011). https://doi.org/10.1007/s11060-010-0519-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0519-8

Keywords

  • Dural sinus vein thrombosis
  • Bevacizumab
  • Anaplastic astrocytoma
  • Venous thromboembolism